Eli Lilly and Ranbaxy Joint Venture: Strategy Analysis
This paper examines the joint venture between Eli Lilly and Company and Ranbaxy Laboratories Limited, two leading pharmaceutical firms operating across distinctly different national and cultural contexts. The analysis considers Ranbaxy's global standing, the potential impact of tightening Indian pharmaceutical regulations on the venture's cash flow and profitability, and Eli Lilly CEO John C. Lechleiter's emphasis on innovation as a guiding strategic value. Drawing on Lilly's 2010 annual report, industry sources, and Lechleiter's published speeches, the paper concludes that Eli Lilly should adopt a wait-and-see approach before taking any corrective action, given that the venture remains profitable and the anticipated regulatory changes have not yet been implemented.
- Introduction: Joint venture context and central strategic question
- Ranbaxy's Global Standing and Joint Venture Background: Ranbaxy's global reach and market presence
- Innovation, Leadership, and Strategic Values: Lechleiter's innovation philosophy and its relevance
- Profitability and Growth of the Joint Venture: Venture history, growth, and mutual benefit
- Regulatory Risk and Its Potential Impact: Indian regulatory changes threatening the venture
- Recommendation and Conclusion: Wait-and-see strategy recommended for Eli Lilly
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- It frames a specific strategic question clearly — whether Eli Lilly should be concerned about Ranbaxy's future — and works toward a concrete, defensible recommendation.
- It draws directly on primary corporate sources, including Lilly's 2010 annual report and 10-K filing, lending credibility to the analysis.
- The paper maintains a balanced tone, acknowledging both the venture's demonstrated profitability and the genuine risks posed by evolving Indian pharmaceutical regulations.
Key academic technique demonstrated
The paper models applied business case analysis: it identifies a managerial decision point, gathers evidence from corporate documents and industry sources, and uses that evidence to argue for a specific course of action. This technique — grounding strategic recommendations in documented financial and regulatory realities rather than speculation — is a core skill in undergraduate business and management writing.
Structure breakdown
The paper opens by establishing the context of the joint venture and the central strategic question. It then surveys Ranbaxy's global profile, introduces Eli Lilly's innovation-driven leadership philosophy, and reviews the venture's historical profitability. A focused section addresses regulatory risk before the paper closes with a concise recommendation. This progression from context to analysis to recommendation follows a classic problem–evidence–solution structure well suited to business case writing.
Introduction
Eli Lilly and Company has maintained a joint venture in India with Ranbaxy Laboratories Limited. Each firm is a leading pharmaceutical company in its respective country, and though each operates within a distinctly different culture, their joint venture worked well until relatively recently. India, like many countries, is changing the business marketplace through increased regulations and stringent standards that make doing business more difficult, which affects Ranbaxy's cash flow and bottom line. This situation could lead to trouble for Eli Lilly and may, at the very least, affect Eli's bottom line as well as Ranbaxy's. The central question, then, is whether Eli Lilly should be worried about the future of Ranbaxy and, if so, what actions Eli should take to alleviate that concern.
Ranbaxy's Global Standing and Joint Venture Background
A recent industry article on Ranbaxy notes that "the company is ranked among the top ten global generic companies and has a presence in 23 of the top 25 pharmaceutical markets of the world" (Industry Watch, 2008, p. 48). The article further describes the company as maintaining a "global footprint in 49 countries, world class manufacturing facilities in 11, and a diverse product portfolio" (p. 48). If these characterizations are accurate, then Eli Lilly likely does not have a great deal to worry about — unless the joint venture is specifically at risk from Ranbaxy's slowing cash flow or from the new regulations that India may choose to implement.
Innovation, Leadership, and Strategic Values
If only John C. Lechleiter could convince the government of India that what is needed is not additional regulation but greater innovation, the joint venture would likely benefit accordingly. Lechleiter is a strong proponent of innovation; in a speech he delivered in late 2010, he stated: "With the help of medical innovation, not only have we purchased additional decades of life and health… but the economic payback from these gains is also difficult to overstate" (Lechleiter, 2011, p. 15). Lechleiter is unlikely to persuade the Indian government to change course as dramatically as he might hope, but his commitment to innovation as a strategic value may ultimately be a deciding factor in whether Eli Lilly chooses to maintain the joint venture with Ranbaxy or terminate the relationship.
References
Eli Lilly (2011). 2010 Annual Report. Retrieved November 20, 2011, from
Industry Watch. (2008). Asia Pacific Biotech News, 12(6), 37–63.
Lechleiter, J. C. (2011). The return on innovation. Vital Speeches of the Day, 77(1), 13–18.
Always verify citation format against your institution’s current style guide requirements.